Loading
IARC estimates 4,076 new cancer cases and 1,719 cancer deaths in Oman in 2024; the commonest new cancers are breast, colorectum and thyroid. This page is assembled automatically from OnCo's data: 3 trials with a site there and 2 institutions, and says what OnCo does not yet hold.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Breast | 589 | 31.9 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Colorectum | 492 | 13.1 | Colorectal cancer |
| Thyroid | 434 | 7.7 | Thyroid cancer |
| Non-Hodgkin lymphoma | 278 | 6.8 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Leukaemia | 210 | 4.6 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Liver and intrahepatic bile ducts | 186 | 6.4 | Hepatocellular carcinoma |
| Prostate | 177 | 15.0 | Prostate cancer |
| Stomach | 169 | 5.7 | Gastric & gastro-oesophageal junction cancer |
| Trachea, bronchus and lung | 165 | 6.1 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Bladder | 141 | 5.1 | Bladder & urothelial cancer |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Colorectum | 209 | 6.1 | Colorectal cancer |
| Liver and intrahepatic bile ducts | 169 | 5.9 | Hepatocellular carcinoma |
| Breast | 148 | 8.7 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Trachea, bronchus and lung | 145 | 5.3 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Leukaemia | 121 | 2.8 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Stomach | 110 | 4.1 | Gastric & gastro-oesophageal junction cancer |
| Non-Hodgkin lymphoma | 101 | 2.8 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Brain, central nervous system | 92 | 2.1 | Glioma & glioblastoma |
| Pancreas | 71 | 2.5 | Pancreatic ductal adenocarcinoma |
| Bladder | 53 | 2.1 | Bladder & urothelial cancer |
| Trial | Lead sponsor | ||||
|---|---|---|---|---|---|
| Phase 3 | Recruiting | Hoffmann-La Roche | 192 | 2026-09-21 | |
| Phase 3 | Active not recruiting | Hoffmann-La Roche | 198 | 2026-10-02 | |
| Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 119 | 2026-08-26 |
Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Oman, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Oman is open is on the registry page, under Contacts and Locations.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Oman is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
Oman is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.